Phaseline

Targets › LCA5

LCA5 (Lebercilin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Jun 2028.

Involved in intraflagellar protein (IFT) transport in photoreceptor cilia. Plays a role in the ciliary transport of photoreceptors outer segment proteins. (UniProt, Q86VQ0)

Open in Phaseline: the race on LCA5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Opus GeneticsOPGx-001
AAV8 vector expressing human LCA5 gene
LCA5Phase 1LCA5Jun 2028

Conditions

LCA5 (1)

Modalities

other (1)

Companies

Opus Genetics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.